Aemetis (AMTX) Posts Earnings Results, Beats Estimates By $0.02 EPS

Aemetis (NASDAQ:AMTX) posted its earnings results on Friday. The specialty chemicals company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.02, MarketWatch Earnings reports. The firm had revenue of $44.64 million during the quarter, compared to the consensus estimate of $43.14 million.

AMTX opened at $0.93 on Friday. Aemetis has a twelve month low of $0.45 and a twelve month high of $3.12.

Several equities research analysts have recently weighed in on AMTX shares. Zacks Investment Research raised shares of Aemetis from a “sell” rating to a “hold” rating in a report on Monday, July 16th. B. Riley set a $2.00 target price on shares of Aemetis and gave the stock a “hold” rating in a report on Monday, August 13th.

ILLEGAL ACTIVITY WARNING: “Aemetis (AMTX) Posts Earnings Results, Beats Estimates By $0.02 EPS” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/11/aemetis-amtx-posts-earnings-results-beats-estimates-by-0-02-eps.html.

Aemetis Company Profile

Aemetis, Inc operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced bio refineries.

See Also: Google Finance Portfolio Workaround

Earnings History for Aemetis (NASDAQ:AMTX)

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply